Now Recruiting:

A Retrospective Study of Natural History Data in
Infants and Toddlers with LAMA2-Congenital Muscular Dystrophy

(Merosin Deficient/MDC1A)


The Study

This is a non‐interventional, retrospective medical chart review study of affected individuals with LAMA2‐CMD. Medical records from approximately 100 participants born between 2000 and 2017 will be reviewed and compiled using the Congenital Muscle Disease International Registry (CMDIR).

Requirements to Participate

  • Confirmed diagnosis of LAMA2‐CMD

  • Born between 2000—2017

  • Medical records available for birth—5 years, with a special interest in birth—2years

  • Records available in English, Spanish, French, Dutch or Arabic

  • Registration in the Congenital Muscle Disease International Registry (CMDIR)

More Information

Study will close upon enrollment of 100 participants.

Please contact the Cure CMD Study Team for more information about this study and how to enroll.


Prothelia Logo.png

ClinicalTrials.GOV listing ID: NCT04299321

The Details

A Retrospective Natural History Study (rNHS) collects health information by reviewing and extracting data from medical records that have been created during the course of medical care, by healthcare providers who have treated the study participant.

While we have cataloged natural history data for affected individuals between 6 and 18 years of age, we do not have data for affected individuals between Birth and 5 years of age.

Some treatments currently in development will almost certainly be more effective the earlier the treatment is administered to the affected individual. In order to obtain regulatory authorization to launch clinical trials in affected individuals less than 6 years of age, we must demonstrate a documented natural history for this age group.

This study will focus specifically on medical records generated for LAMA2‐CMD affected individuals between birth and 5 years of age, to build our catalog of natural history data in the pediatric LAMA2‐CMD population, in order to provide adequate evidence to regulatory agencies who will determine whether or not a clinical trial for a treatment or intervention may be initiated. No travel is required, and no treatment will be provided.


Aspire IRB Protocol #20200260, Approved 19 Feb 2020